Victoria Wong, PA
Medical · Philadelphia, PANPI 1437693918
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $34,961 of the $51,400 with a category attached, or 68.0%. Johnson & Johnson accounts for 65.9% of it on its own, with 22 other manufacturers making up the rest. 2025 is the largest year on record at $18,660, more than ten times the $1,013 reported in 2021. Among medical clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 259 payments — averaging $198.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$34K
- Exelixis Inc.$12K
- Bayer$1K
- Pfizer$959
- Seagen Inc.$927
- AstraZeneca$825
- plus $2K from 17 others
What the payments were for
- Consulting fees$4,93110%
- Speaking & faculty fees$34,96168%
- Travel & lodging$3,9068%
- Food & beverage$7,60215%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 91 | $33,897 |
| Exelixis Inc. | 46 | $11,681 |
| Bayer | 26 | $1,151 |
| Pfizer | 11 | $959 |
| Seagen Inc. | 4 | $927 |
| AstraZeneca | 20 | $825 |
| E.r. Squibb & Sons, L.L.C. | 4 | $429 |
| Daiichi Sankyo Inc. | 11 | $273 |
| Gilead | 4 | $234 |
| Myovant Sciences Inc. | 8 | $195 |
| Merck | 7 | $147 |
| Astellas Pharma US Inc | 3 | $144 |
| Novartis | 7 | $134 |
| Sanofi | 3 | $101 |
| Eisai Inc. | 5 | $88 |
| Mirati Therapeutics, Inc. | 2 | $41 |
| Biohaven Pharmaceuticals, Inc. | 1 | $38 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $30 |
| Sumitomo Pharma America, Inc. | 1 | $29 |
| Tolmar Pharmaceuticals, Inc. | 1 | $28 |
| Genmab U.S., Inc. | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Clovis Oncology, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$51,400 in reported general payments places this provider in the 95th percentile of 2,594 medical providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisone | 66 | $386 |
| Amlodipine Besylate | 19 | $141 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 13 | $79 |
| Tramadol Hcl | 11 | $27 |
Paid to pharmacies, not to this prescriber.
Other medical in Philadelphia
- Angela KapalkoPhiladelphia$123K
- Linda PerryPhiladelphia$123K
- Sarah SmithPhiladelphia$65K
- Parth PatelPhiladelphia$46K
- Zachary LutzPhiladelphia$30K
- Hawah MusaPhiladelphia$13K
- Carl BlackPhiladelphia$13K
- Ashley BarratPhiladelphia$12K
- Jacqueline KernaghanSpringfield$426K
- Drew SodaNew Hope$220K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.